Capital International Investors
SRPT icon

Capital International Investors’s Sarepta Therapeutics SRPT Stock Holding History

Capital International Investors’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-498,337
Closed -$8.52M – 469
2025
Q2 		$8.52M Sell
498,337
-8,562,435
-95% -$365M ﹤0.01% 401
2025
Q1 		$578M Buy
9,060,772
+363,635
+4% +$38.3M 0.11% 149
2024
Q4 		$1.06B Buy
8,697,137
+2,437,855
+39% +$299M 0.2% 105
2024
Q3 		$782M Buy
6,259,282
+1,938,455
+45% +$268M 0.15% 133
2024
Q2 		$683M Sell
4,320,827
-496,690
-10% -$63.8M 0.14% 137
2024
Q1 		$624M Buy
4,817,517
+76,032
+2% +$9.31M 0.13% 148
2023
Q4 		$457M Buy
4,741,485
+2,917,797
+160% +$280M 0.1% 167
2023
Q3 		$221M Buy
+1,823,688
New +$206M 0.06% 212
2021
Q1 		– Sell
-151,678
Closed -$25.9M – 464
2020
Q4 		$25.9M Buy
151,678
+55
+0% +$8.15K 0.01% 374
2020
Q3 		$21.3M Hold
151,623
– – 0.01% 367
2020
Q2 		$24.3M Buy
151,623
+6,895
+5% +$938K 0.01% 343
2020
Q1 		$14.2M Buy
+144,728
New +$16.5M 0.01% 336

Other funds holding SRPT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Capital International Investors's SRPT Position: Q3 2025 in Review

Capital International Investors sold out of Sarepta Therapeutics (SRPT) in Q3 2025, closing a stake of 498,337 shares — an estimated $8.52M sold.

Capital International Investors first reported a position in SRPT in Q1 2020 and held it in 12 quarters. The position peaked at $1.06B in Q4 2024. 320 funds tracked by Wall St. Rank hold SRPT as of Q3 2025.

  • Capital International Investors reported no remaining Sarepta Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Capital International Investors sold 498,337 Sarepta Therapeutics shares in Q3 2025, an estimated $8.52M.
  • Capital International Investors first reported a position in Sarepta Therapeutics in Q1 2020 and held it in 12 quarters.
  • Capital International Investors's Sarepta Therapeutics position peaked at $1.06B in Q4 2024.
  • 320 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q3 2025.

Based on Capital International Investors's 13F filing for Q3 2025, filed 13 Nov 2025.